Created by Endomag

🇬🇧 UK
🇺🇸 US

Get in touch

What if up to 80% of high risk DCIS patients could avoid unnecessary underarm surgery?

Introducing the 'Delayed' SLNB technique. Only with Magtrace®.

There is now a new way to avoid SLNB for high-risk DCIS patients

Every year, hundreds of thousands of women across the world are diagnosed with ductal carcinoma in-situ (DCIS).

The standard treatment for high-risk patients is to remove the DCIS, and at the same time perform a sentinel lymph node biopsy (SLNB).

But could less treatment be better for both patients and clinicians?

The 'delayed' sentinel
lymph node biopsy

Pioneering clinical studies now show that it is possible for many high-risk DCIS patients to avoid a SLNB altogether.

The way forward involves the Magtrace® lymphatic tracer and a new technique called delayed sentinel lymph node biopsy (dSLNB), which allows you to hold off on performing axillary surgery until you know you need to.

How does it work?

Magtrace® is injected into the breast prior to surgery to mark the sentinel lymph nodes. It has been designed to remain in the nodes for many weeks (unlike other tracers).

The patient will then undergo a mastectomy, with the DCIS sent for pathological analysis. SLNB is not performed at this stage.

Is the surgery necessary?

If the DCIS is proven to be non-invasive, no further axillary surgery is required. Nodes are saved.

If the DCIS is invasive, the lymph nodes have remained marked and can be operated on in due course.

Use our calculator to find out more

THE CLINICAL DATA

SentiNOT –
The study that revolutionised axilla management

Delayed SLNB is now routinely used around the world, but it all began with one groundbreaking study led by Dr. Andreas Karakatsanis – SentiNOT.

250+

High-risk DCIS
patients

28 days

Median time from
injection to surgery

78.7%

Patients avoiding
SLNB

98.2%

Detection rate,
when returning

Karakatsanis et al (2023)

Delayed Sentinel Lymph Node Dissection in Patients with a Preoperative Diagnosis...

Read the full clinical paper

Demanded
by Patients

Meet Jeri, a former breast cancer survivor and patient advocate who had the opportunity to avoid a SLNB.

"There was minimal discomfort. It was basically pain-free. I believe that this will be a gamechanger for surgical treatment in breast cancer."

Meet Holly, her concerns about how axillary surgery could affect her lifestyle led her to consider all options available.

"I hope other patients ask about it [Delayed SLNB] because it really is such a simple solution, and has been life-changing for me."

Surgical
Pioneers

Dr. Julie Margenthaler, MD, FACS

St. Louis, Missouri [USA]

"Now with Magtrace, we can really do a delayed sentinel node procedure only for those who need it, and the rest of the patients can avoid the morbidity of that procedure when it's really not necessary..."

Dr. Kandace McGuire, MD

Richmond, Virginia [USA]

"...when I tell patients that they're going to get Magtrace, I tell them what the alternative would be, and why we're using one versus the other. And I think that they are very appreciative."

Mr. Ricardo Pardo-Garcia

Bolton, Lancashire [UK]

"...if the result of the mastectomy comes back as [non-invasive] DCIS, we don't do anything else. So we avoid doing that sentinel lymph node biopsy in all those cases."


Dr. Emilia Dauway, MD, FACS, FRACS

Hervey Bay, Queensland [AUS]

"...if we can eliminate that risk [of lymphedema] altogether for 80% of patients that have high risk DCIS, I think that's quite significant."


View more videos

Get in touch

© Endomagnetics Ltd (Endomag) is a company registered in England and Wales (No. 06227698).
Registered Office: 330 Cambridge Science Park, Cambridge, CB4 0WN, United Kingdom. VAT Registration No: GB 947 7709 68

Privacy Policy

Terms of Use